KeyBanc analyst Scott Schoenhaus raised the firm’s price target on Phreesia to $45 from $40 and keeps an Overweight rating on the shares. With outsized revenue growth into a large market opportunity and clear pathway to return to profitability, the firm sees Phreesia as one of the most attractive "beat and raise" stories in its coverage universe.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on PHR:
- Piper ups Phreesia target, names top pick for 2023
- Piper Sandler healthcare tech analysts to hold analyst/industry conference call
- Phreesia named 2023 Top Pick, added to Conviction List at Needham
- Baird staying selective in vertical software, makes four rating changes
- Phreesia upgraded to Buy at Citi on ‘clearer path to profitability’
